Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lokelma (sodium zirconium cyclosilicate) is an anti-hyperkalaemia (HK) therapy that provides rapid potassium reduction and sustained potassium control.15 It is indicated for the treatment of Hyperkalaemia (HK) in adults.
Product Name : Lokelma
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2023
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Update on CRYSTALIZE Evidence Trials
Details : Lokelma (sodium zirconium cyclosilicate) is an anti-hyperkalaemia (HK) therapy that provides rapid potassium reduction and sustained potassium control.15 It is indicated for the treatment of Hyperkalaemia (HK) in adults.
Product Name : Lokelma
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 12, 2023
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The designation is based on the potential of LOKELMA to reduce serious adverse CV outcomes in this patient population, addressing a significant unmet medical need.
Product Name : Lokelma
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 17, 2021
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approval by the NMPA was based on data from the Phase IIIb DIALIZE trial. The trial showed sustained potassium control pre-dialysis for more patients receiving Lokelma, compared with placebo.
Product Name : Lokelma
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 24, 2020
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The 20 abstracts being presented, will include data on Lokelma (sodium zirconium cyclosilicate), roxadustat & Farxiga (dapagliflozin) across different stages of CKD and AstraZeneca’s ongoing commitment to exploring treatment options across the full con...
Product Name : Lokelma
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 06, 2020
Lead Product(s) : Sodium Zirconium Cyclosilicate
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable